Thursday - October 31, 2024
Purdue University: Biotech Company Eradivir Closes $10.25M Series A Funding Round to Complete Phase 2a Study of Influenza Therapeutic
September 25, 2024
WEST LAFAYETTE, Indiana, Sept. 25 (TNSres) -- Purdue University issued the following news release:

Eradivir, a preclinical biotech company that develops antiviral therapeutics, has completed a $10.25 million Series A funding round. The funding will be used to conduct a Phase 2a challenge study of its EV25 influenza treatment.

CEO Martin Low said EV25 consistently outperforms the current standard of care for influenza in preclinical models.

"Within 24 h . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation
Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products